Researchers from Oslo University Hospital Detail Research in Prostate Cancer (A case of severe side effects to androgen receptor inhibitor and consequently switch to radioligand therapy in early castration resistant prostate cancer).

Předmět:	CASTRATION-resistant prostate cancer PROSTATE cancer ANDROGEN receptors UNIVERSITY hospitals RESEARCH personnel DNA-binding proteins
Zdroj:	Clinical Oncology Week; 5/28/2024, p714-714, 1p
Abstrakt:	A research study conducted at Oslo University Hospital in Norway explores the use of radioligand therapy (RLT) as an alternative treatment for castration-resistant prostate cancer (CRPCa) patients who experience severe side effects from androgen receptor inhibitors (ARi). The study highlights the potential benefits of early RLT in PSMA avid tumors, as it resulted in prolonged progression-free survival with minimal side effects compared to chemotherapy. The findings suggest that RLT could be a viable treatment option for CRPCa patients who cannot tolerate ARi. Further information on the study can be found in the Urology Case Reports journal. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu